IMW 2019 | WM: BTK inhibitors
Jorge Castillo and Ramon Garcia-Sanz
• 14 Sep 2019
From the International Myeloma Workshop (IMW) 2019, held in Boston, MA, Jorge Castillo, MD, from Dana-Farber Cancer Institute, Boston, MA, and Ramon Garcia-Sanz, MD, from University Hospital of Salamanca, Salamanca, Spain, discuss the exciting new agents for the treatment of Waldenström’s Macroglobulinemia (WM) that are emerging from current clinical trials. This discussion highlights venetoclax, ibrutinib and newer BTK (Bruton tyrosine kinase) inhibitors such as acalabrutinib and zanubrutinib.
